FCF Grants Awarded in 2023
Total grants: 8
- Molecular therapies for fibrolamellar carcinoma (FLC) – continuation — Principal investigator(s): John Scott — University of Washington
- Exploiting a Critical Vulnerability to Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC) — Principal investigator(s): Marina Baretti, Mark Yarchoan — Johns Hopkins University and Dracen Pharmaceuticals
- CRISPR-engineering of human liver organoids to study fibrolamellar carcinoma — Principal investigator(s): Benedetta Artegiani, Delilah Hendriks — Princess Maxima Center for Pediatric Oncology
- Development and Characterization of Patient-derived Models of Fibrolamellar Carcinoma — Principal investigator(s): Taran Gujral — Fred Hutchinson Cancer Center
- Selective translational inhibition as a treatment strategy for fibrolamellar liver cancer — Principal investigator(s): John Gordan — University of California at San Francisco
- Therapeutic modulation of tumor-infiltrating T cell function in fibrolamellar carcinoma — Principal investigator(s): Venu Pillarisetty, Kevin Barry — University of Washington
- Development of pre-clinical murine models for fibrolamellar hepatocellular carcinoma — Principal investigator(s): Julien Sage — Stanford University
- How fibrolamellar carcinoma differs from hepatocellular carcinoma in children – Creation of a multi-institutional database including central pathologic review — Principal investigator(s): Roshni Dasgupta — Cincinnati Children's Hospital Medical Center
This list represents the complete set of Fibrolamellar Cancer Foundation grants awarded in 2023. The name of the grant is listed, along with the institution receiving the grant and the principal investigator.